Abstract
There is a lack of multi-center cost-identification studies for hematopoietic cell transplantation (HCT). We used a single longitudinal administrative claims database representing a national, commercially insured population to evaluate the feasibility of identifying HCT recipients and to establish a cohort of autologous and allogeneic HCT recipients to study inpatient and outpatient direct medical costs from transplant hospitalization through first 100 days post-transplantation. Using ICD-9 procedure and diagnosis codes, we identified 3365 patients who had received their first transplant in the United States between 2007 and 2009 (autologous, 1678, allogeneic, 1320, graft source not specified, 367). The median 100-day total costs for autologous HCT were $99 899 (interquartile range (IQR), $73 914–140 555), and for allogeneic HCT were $203 026 (IQR, $141 742–316 426). The majority of costs (>75%) occurred during the initial transplant hospitalization for both autologous and allogeneic HCT recipients. Costs were greater among pediatric (⩽20 years) compared with adult (>20 years) recipients and this difference was more pronounced with allogeneic HCT. Using a claims database representing a national HCT population, we highlight the high costs associated with autologous and allogeneic HCT. Our study lays the foundation for using claims data for future research on economic aspects of HCT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Stranges E, Russo CA, Friedman B . Procedures with the most rapidly increasing hospital costs, 2004–2007, HCUP Statistical Brief #82. December 2009. Agency for Healthcare Research and Quality: Rockville, MD. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb82.pdf.
Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ . Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant 2009; 15: 564–573.
Majhail NS, Mothukuri JM, Macmillan ML, Verneris MR, Orchard PJ, Wagner JE et al. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer 2010; 54: 138–143.
Lee SJ, Anasetti C, Kuntz KM, Patten J, Antin JH, Weeks JC . The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood 1998; 92: 4047–4052.
Lee SJ, Klar N, Weeks JC, Antin JH . Predicting costs of stem-cell transplantation. J Clin Oncol 2000; 18: 64–71.
Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP et al. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant 2008; 14: 197–207.
Saito AM, Zahrieh D, Cutler C, Ho VT, Antin JH, Soiffer RJ et al. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant 2007; 40: 209–217.
Bennett C, Waters T, Stinson T, Almagor O, Pavletic Z, Tarantolo S et al. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 555–560.
Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB . Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol 1999; 17: 2811–2818.
Lee SJ, Astigarraga CC, Eapen M, Artz AS, Davies SM, Champlin R et al. Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008; 14: 1231–1238.
Lee SJ, Joffe S, Artz AS, Champlin RE, Davies SM, Jagasia M et al. Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol 2008; 26: 2162–2170.
Majhail NS, Murphy EA, Omondi NA, Majhail NS, Murphy EA, Omondi NA et al. Allogeneic transplant physician and center capacity in the United States. Biol Blood Marrow Transplant 2011; 17: 956–961.
Iezzoni LI . Assessing quality using administrative data. Ann Intern Med 1997; 127: 666–674.
Riley GF . Administrative and claims records as sources of health care cost data. Med Care 2009; 47: S51–S55.
Etzioni R, Riley GF, Ramsey SD, Brown M . Measuring costs: administrative claims data, clinical trials, and beyond. Med Care. 2002; 40: III63–III72.
Jones JA, Qazilbash MH, Shih YC, Cantor SB, Cooksley CD, Elting LS . In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies: clinical and economic outcomes from the Nationwide Inpatient Sample. Cancer 2008; 112: 1096–1105.
McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878–1887.
Acknowledgements
Funding Support for this study was provided by the Cancer Outcomes and Survivorship Pilot Grant through the University of Minnesota Masonic Cancer Center. The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; and grants from AABB; Allos, Inc.; Amgen, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US, Inc.; Be the Match Foundation; Biogen IDEC; BioMarin Pharmaceutical, Inc.; Biovitrum AB; BloodCenter of Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow Foundation; Buchanan Family Foundation; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Children’s Leukemia Research Association; ClinImmune Labs; CTI Clinical Trial and Consulting Services; Eisai, Inc.; Genentech, Inc.; Genzyme Corporation; Histogenetics, Inc.; HKS Medical Information Systems; Hospira, Inc.; Kirin Brewery Co., Ltd.; The Leukemia & Lymphoma Society; Merck & Company; The Medical College of Wisconsin; Millennium Pharmaceuticals, Inc.; Miller Pharmacal Group; Milliman USA, Inc.; Miltenyi Biotec, Inc.; National Marrow Donor Program; Nature Publishing Group; Novartis Oncology; Oncology Nursing Society; Osiris Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Pall Life Sciences; Pfizer Inc; Schering Corporation; Sigma-Tau Pharmaceuticals; Soligenix, Inc.; StemCyte, Inc.; StemSoft Software, Inc.; Sysmex America, Inc.; THERAKOS, Inc.; Vidacare Corporation; ViraCor Laboratories; ViroPharma, Inc.; and Wellpoint, Inc. The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, or any other agency of the U.S. Government.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on Bone Marrow Transplantation website
Supplementary information
Rights and permissions
About this article
Cite this article
Majhail, N., Mau, L., Denzen, E. et al. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: a study using a large National Private Claims Database. Bone Marrow Transplant 48, 294–300 (2013). https://doi.org/10.1038/bmt.2012.133
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.133
Keywords
This article is cited by
-
Total and out-of-pocket expenditures for patients undergoing hematopoietic cell transplantation
Bone Marrow Transplantation (2023)
-
Melatonin enhances autologous adipose-derived stem cells to improve mouse ovarian function in relation to the SIRT6/NF-κB pathway
Stem Cell Research & Therapy (2022)
-
Cost of HSCT in a Tertiary Care Public Sector Hospital in India
Indian Journal of Hematology and Blood Transfusion (2022)
-
Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis
BMC Health Services Research (2021)
-
Wiskott Aldrich syndrome: healthcare utilizations and disparities in transplant care
Scientific Reports (2021)